The certification has the potential to open access to Islamic markets globally, expanding potential markets for Scilex's innovative FDA approved non-opioid therapies and pipeline candidate products.
The certification is an important prerequisite for health care and covers health and wellness as well as non-addictive pain management products.
Announcement advances the global expansion strategy for Scilex with plans for growing its presence in the Middle East and North Africa region with an initial focus on the UAE and Saudi Arabia.
PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it received Halal Certification of its commercial product ZTlido, indicating that ZTlido has undergone rigorous assessment to determine that it is permissible or acceptable in accordance with Islamic standards. The Halal certification was issued under the authority of Circle H International, Inc. ("Circle H") and offers the Company the opportunity to provide ZTlido to Islamic markets globally. This announcement supports the global expansion strategy for Scilex, which Scilex anticipates will include a presence in the Middle East and North Africa (MENA) region with an initial priority focus on the UAE and Saudi Arabia.
"Obtaining the broadly inclusive Halal Certification is a critical and important milestone in Scilex's plan to expand to potential Islamic markets for our innovative non-opioid non-addictive pain management therapeutic pipeline candidates and FDA approved products. With the global Muslim population representing over 25% of the world's population, according to Statista, this certification facilitates our ability to grow and expand in international markets," said Jaisim Shah, Chief Executive Officer and President of Scilex.
Circle H issued the Halal Certification based on the global standards promulgated by its esteemed Circle H Sharia Advisory Council (the "Council"). Circle H and the Council are recognized and supported by prominent governmental and non-governmental organizations and Islamic universities. Religious leaders drawn from these prominent institutions sit on or advise Circle H and the Council, for the development and support of its Halal standards.
該認證有可能在全球範圍內打開進入伊斯蘭市場的機會，擴大Scilex經美國食品藥品管理局批准的創新非阿片類藥物療法和管道候選產品的潛在市場。
該認證是醫療保健的重要先決條件，涵蓋健康和保健以及非成癮性疼痛管理產品。
該公告推進了Scilex的全球擴張戰略，計劃擴大其在中東和北非地區的業務，最初的重點是阿聯酋和沙特阿拉伯。
加利福尼亞州帕洛阿爾託，2024年3月15日（GLOBE NEWSWIRE）——專注於收購、開發和商業化用於治療急慢性疼痛的非阿片類疼痛管理產品的創新創收公司Scilex控股公司（納斯達克股票代碼：SCLX，“Scilex” 或 “公司”）今天宣佈，其商業產品ZTLido已獲得清真認證，這表明ZTLido已獲得清真認證經過嚴格評估，以確定根據伊斯蘭標準是允許的還是可以接受的。清真認證是在Circle H International, Inc.（“Circle H”）的授權下頒發的，爲公司提供了向全球伊斯蘭市場提供ztLido的機會。該公告支持Scilex的全球擴張戰略，Scilex預計該戰略將包括在中東和北非（MENA）地區開展業務，最初的優先重點是阿聯酋和沙特阿拉伯。
“獲得廣泛包容的清真認證是Scilex計劃將我們的創新非阿片類非成癮性疼痛管理候選藥物和FDA批准的產品擴展到潛在的伊斯蘭市場的關鍵而重要的里程碑。根據Statista的數據，全球穆斯林人口占世界人口的25％以上，該認證促進了我們在國際市場上增長和擴張的能力。” Scilex首席執行官兼總裁賈西姆·沙阿說。
Circle H根據其尊敬的Circle H伊斯蘭教法諮詢委員會（“理事會”）頒佈的全球標準發佈了清真認證。Circle H和理事會得到著名政府和非政府組織以及伊斯蘭大學的認可和支持。來自這些知名機構的宗教領袖擔任Circle H和理事會的成員，或向其提出建議，以制定和支持其清真標準。
